Company: RVRC
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-013823
Chunk: 25

Company: Revium Rx.
Filing Date: 2025-02-14
Form: S-1
Chunk 25
---
 could have a material adverse effect on our ability to market or sell our brands, profitably exploit our products or recoup our associated research and development costs.

<div align='center'>14</div>

The patenting process, enforcement of issued patents, and defense against claims of infringement are inherently risky.

The strength of our patent portfolio is an important factor that will influence our success. Securing patents for the ARB adjuvant technology is essential for safeguarding investment and maintaining competitiveness in the market. Patents give the patent holder the right to prevent others from using its patented technology. If someone infringes upon the patented material of a patent holder, the patent holder has the right to initiate legal proceedings against that person to protect its patented material. These proceedings, however, can be lengthy and costly. We perform an ongoing review of our patent portfolio to confirm that our key technologies are adequately protected. If we determine that any of our patents require either additional disclosures or revisions to existing information, we may ask that such patents be reexamined or reissued, as applicable, by the United States Patent and Trademark Office.

Because we rely heavily on patent protection, we face the following significant risks:

| ● | Possibility                                                                                   
 of Inadequate Patent Protection for Product. The United States Patent and Trademark Office    
 or foreign patent offices may not grant patents of meaningful scope based on the applications 
 we have already filed and those we intend to file. If we do not have patents that adequately  
 protect our human-use equipment and indications for its use, then we will not be competitive. |

| ● | Potential                                                                                        
 That Important Patents Will Be Judged Invalid. Some of the issued patents (issued patents        
 cannot be invalid only provisional applications or know how we now own or license may be         
 determined to be invalid. If we have to defend the validity of any of our patents, the costs     
 of such defence could be substantial, and there is no guarantee of a successful outcome.         
 In the event an important patent related to our drug delivery technology is found to be invalid, 
 we may lose competitive position and may not be able to receive royalties for products covered   
 in part or whole by that patent under license agreements.                                        |

| ● | Danger                                                                                               
 of Being Charged With Infringement. Although we are not currently aware of any parties               
 intending to pursue infringement claims against us, there is the possibility that we may             
 use a patented technology owned by another person and/or be charged with infringement. Defending     
 or indemnifying